These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 22016502)

  • 41. HIV/AIDS-related visceral leishmaniasis: a clinical and epidemiological description of visceral leishmaniasis in northern Brazil.
    Albuquerque LC; Mendonça IR; Cardoso PN; Baldaçara LR; Borges MR; Borges Jda C; Pranchevicius MC
    Rev Soc Bras Med Trop; 2014; 47(1):38-46. PubMed ID: 24603735
    [TBL] [Abstract][Full Text] [Related]  

  • 42. AmBisome Monotherapy and Combination AmBisome-Miltefosine Therapy for the Treatment of Visceral Leishmaniasis in Patients Coinfected With Human Immunodeficiency Virus in India: A Randomized Open-Label, Parallel-Arm, Phase 3 Trial.
    Burza S; Mahajan R; Kazmi S; Alexander N; Kumar D; Kumar V; Lasry E; Harshana A; de Lima Pereira A; Das P; Verma N; Das VNR; Lal CS; Rewari B; Goyal V; Rijal S; Alves F; Gill N; Pandey K
    Clin Infect Dis; 2022 Oct; 75(8):1423-1432. PubMed ID: 35147680
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The clinical and evolutional characteristics of visceral leishmaniasis in patients with HIV infection].
    Delgado Fernández M; García Ordoñez MA; Martos Pérez F; Reguera Iglesias JM; Jiménez Oñate F; Colmenero Castillo JD
    An Med Interna; 1997 Oct; 14(10):506-10. PubMed ID: 9424140
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.
    López-Vélez R; Videla S; Márquez M; Boix V; Jiménez-Mejías ME; Górgolas M; Arribas JR; Salas A; Laguna F; Sust M; Cañavate C; Alvar J;
    J Antimicrob Chemother; 2004 Mar; 53(3):540-3. PubMed ID: 14739148
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study.
    Mondal D; Alvar J; Hasnain MG; Hossain MS; Ghosh D; Huda MM; Nabi SG; Sundar S; Matlashewski G; Arana B
    Lancet Glob Health; 2014 Jan; 2(1):e51-7. PubMed ID: 25104636
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ambisome plus miltefosine for Indian patients with kala-azar.
    Sundar S; Sinha PK; Verma DK; Kumar N; Alam S; Pandey K; Kumari P; Ravidas V; Chakravarty J; Verma N; Berman J; Ghalib H; Arana B
    Trans R Soc Trop Med Hyg; 2011 Feb; 105(2):115-7. PubMed ID: 21129762
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg/kg/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia.
    Tamiru A; Mohammed R; Atnafu S; Medhin G; Hailu A
    PLoS Negl Trop Dis; 2021 Aug; 15(8):e0009713. PubMed ID: 34464401
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial.
    Khalil EA; Weldegebreal T; Younis BM; Omollo R; Musa AM; Hailu W; Abuzaid AA; Dorlo TP; Hurissa Z; Yifru S; Haleke W; Smith PG; Ellis S; Balasegaram M; EL-Hassan AM; Schoone GJ; Wasunna M; Kimutai R; Edwards T; Hailu A
    PLoS Negl Trop Dis; 2014; 8(1):e2613. PubMed ID: 24454970
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan.
    Atia AM; Mumina A; Tayler-Smith K; Boulle P; Alcoba G; Elhag MS; Alnour M; Shah S; Chappuis F; van Griensven J; Zachariah R
    Trop Med Int Health; 2015 Dec; 20(12):1674-84. PubMed ID: 26427033
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Amphotericin B therapy in children with visceral leishmaniasis: daily vs. alternate day, a randomized trial.
    Singh UK; Prasad R; Jaiswal BP; Singh PK; Thakur CP
    J Trop Pediatr; 2010 Oct; 56(5):321-4. PubMed ID: 20065047
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions.
    Sundar S; Chakravarty J; Rai VK; Agrawal N; Singh SP; Chauhan V; Murray HW
    Clin Infect Dis; 2007 Sep; 45(5):556-61. PubMed ID: 17682988
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009].
    Rosenthal E; Delaunay P; Jeandel PY; Haas H; Pomares-Estran C; Marty P
    Med Mal Infect; 2009 Oct; 39(10):741-4. PubMed ID: 19783391
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Central role of interleukin-15 in human immunodeficiency virus (HIV)-infected patients with visceral leishmaniasis.
    d'Ettorre G; Ceccarelli G; Carnevalini M; Forcina G; Zaffiri L; Massetti AP; Mastroianni CM; Vullo V
    Acta Trop; 2006 Aug; 99(1):83-7. PubMed ID: 16962979
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of leishmaniasis in HIV-positive patients.
    Laguna F
    Ann Trop Med Parasitol; 2003 Oct; 97 Suppl 1():135-42. PubMed ID: 14678640
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Diffuse cutaneous dissemination of visceral leishmaniasis during human immunodeficiency virus (HIV) infection, despite negligible immunodeficiency: repeated failure of liposomal amphotericin B administration, followed by successful long-term pentamidine and paromomycin administration.
    Manfredi R; Marinacci G; Calza L; Passarini B
    Int J Antimicrob Agents; 2008 Jun; 31(6):590-2. PubMed ID: 18456464
    [No Abstract]   [Full Text] [Related]  

  • 56. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
    Rihl M; Stoll M; Ulbricht K; Bange FC; Schmidt RE
    J Infect; 2006 Jul; 53(1):e25-7. PubMed ID: 16274744
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Liposomal amphotericin B as first line and secondary prophylactic treatment for visceral leishmaniasis in a patient infected with HIV.
    Borrelli P; Imperato A; Murdaca G; Scudeletti M
    Ann Ital Med Int; 2000; 15(2):169-71. PubMed ID: 10920508
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Visceral leishmaniasis affects liver and spleen concentrations of amphotericin B following administration to mice.
    Gershkovich P; Wasan EK; Sivak O; Li R; Zhu X; Werbovetz KA; Tidwell RR; Clement JG; Thornton SJ; Wasan KM
    J Antimicrob Chemother; 2010 Mar; 65(3):535-7. PubMed ID: 20026611
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations.
    Sundar S; Mehta H; Suresh AV; Singh SP; Rai M; Murray HW
    Clin Infect Dis; 2004 Feb; 38(3):377-83. PubMed ID: 14727208
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical and epidemiological features of visceral leishmaniasis and HIV co-infection in fifteen patients from Brazil.
    Daher EF; Fonseca PP; Gerhard ES; Leitão TM; Silva Júnior GB
    J Parasitol; 2009 Jun; 95(3):652-5. PubMed ID: 19642802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.